Insider buying last 90 days
No open-market insider purchases were filed for LNTH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every LNTH insider filing, plotted on the chart in Gekko.Open LNTH in Gekko
NASDAQ: LNTH
Lantheus (LNTH) Stock Analysis & Forecast
Sep 28 close
$99.740.00 (0.0%)
Gekko Brief
AI summaryLantheus this week centers on regulatory and pipeline progress alongside takeover speculation. The FDA granted final approval for BRAVNETSA (lutetium Lu 177 dotatate) for adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, a decision reiterated across multiple reports. Separately, the company dosed its first patient in the SPARROW Phase 2/3 registrational trial for its GRPR-targeted PET imaging program in prostate cancer, and coverage has referenced intensified takeover interest from Curium Pharma along with a pending shareholder vote. A shareholder-rights investigation into the board was also noted.
The stock closed at $99.74, sitting between its 50-day average of $101.23 and 200-day average of $87.36, reflecting a mixed short-term trend against a stronger longer-term uptrend. The GekkoIndex reads 65.7, placing it in the Accumulation zone. Gekko Fair Value stands at $172.53, putting the current price 42.2% below that level.
Earnings are scheduled for 5 November, 37 days out and beyond a typical 20-trading-day holding window; the prior report showed EPS of $1.67 against a $1.16 estimate with a 1.1% reaction. Smart-money data shows no insider or Congressional trades in the past 90 days and no unusual options signals in the past 30 days. Seasonality over five years shows a 1.7% average 20-day return from this point, positive in 3 of those years. Analyst consensus sits at 9 firms, with 8 hold ratings, 1 buy, and a consensus target of $107.74.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Lantheus price vs fair value
Close $99.74200-day averageGekko Fair Value $172.53
Lantheus quick facts
- Market cap
- $6.49B
- P/E ratio
- 23.9
- Forward P/E
- 14.3
- EPS, TTM
- $4.18
- Revenue, TTM
- $1.56B
- Profit margin
- 17.7%
- Dividend yield
- —
- Beta
- -0.03
- Volume
- 1.20M avg 942,532
- 1-year return
- +93.8%
- Typical daily move
- ±0.4%
- Typical 20-day move
- ±9.2%
- 50-day average
- $101.23
- 200-day average
- $87.36
- Next earnings
- Nov 5 before open
- Shares outstanding
- 65.30M
Lantheus swing-trade checklist
Lantheus scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $99.74 sits between the 50-day ($101.23) and 200-day ($87.36) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
65.7, Accumulation
Reading 65.7 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
42.2% below
Price is 42.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+1.7% on average
From this point in the calendar, the next 20 trading days averaged +1.7% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Lantheus stock chart and price history
Lantheus closed at $99.74 on Sep 28, 2026, +93.8% over the past year, inside a 52-week range of $49.67 to $111.86.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −0.7%
- 3 months
- −9.0%
- 6 months
- +33.9%
- 1 year
- +93.8%
The full LNTH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LNTH in Gekko
Follow Lantheus through every session
Put LNTH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track LNTH in GekkoFree for 7 days. No credit card required.
About Lantheus
Lantheus develops, manufactures and sells diagnostic and therapeutic agents used by clinicians to identify and treat conditions such as heart disease and cancer. Its diagnostic lineup includes DEFINITY for cardiac ultrasound imaging, TechneLite and Cardiolite for nuclear medicine, Xenon-133 for lung function testing, Neurolite for locating stroke damage, Thallium-201 for cardiovascular detection, Gallium-67 for spotting infection and tumors, and PYLARIFY, used to find recurrent or spreading prostate cancer. It is also associated with the Automated Bone Scan Index for measuring prostate cancer in bone scans.
Beyond diagnostics, the company markets AZEDRA, a radiopharmaceutical therapy for adult and pediatric patients, and RELISTOR, used for opioid-induced constipation. Its pipeline covers agents still in development, including flurpiridaz F 18 for blood flow assessment, 1095 and LMI 1195 for tumor targeting, PYLARIFY AI software for analyzing prostate cancer scans, and leronlimab, an antibody under investigation. Customers include radiopharmacies, distributors, hospitals, clinics, integrated delivery networks and group practices, and the company works with partners such as GE Healthcare, Bayer, Curium, FUJIFILM and Regeneron, among others.
Lantheus was established in 1956 and is headquartered in North Billerica, Massachusetts. Its shares are listed on the NASDAQ under the ticker LNTH.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- lantheus.com
Lantheus GekkoIndex: the smart money zone
Lantheus’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.7, in the Accumulation zone, up 4.9 points over five sessions.
65.7Accumulation
Up 4.9 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 39 | −0.4% | +5.1% | ||
| Accumulation (current zone) | 176 | +0.9% | +4.4% | ||
| Neutral | 412 | +0.8% | +2.6% | ||
| Distribution | 37 | +0.9% | +0.4% | ||
| Selling | 8 | Too few readings yet | |||
Average LNTH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the LNTH price, zone by zone.Track LNTH in Gekko
Is Lantheus stock overvalued? Gekko Fair Value
Lantheus trades 42.2% below Gekko Fair Value of $172.53, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Lantheus shares are worth, recalculated every trading day.
$172.53
Gekko Fair Value, Sep 26, 2026
42.2% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open LNTH in Gekko
Lantheus insider and Congress trading
No open-market insider purchases were filed for Lantheus, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in LNTH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for LNTH, plotted on the chart in Gekko.Open LNTH in Gekko
Buybacks
Lantheus has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2025
- $100.0M
- As a share of market cap
- 1.54%
From company filings.
Hedge funds and billionaires quarter ended Sep 30
0of the funds Gekko tracks hold LNTH.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Lantheus earnings: next date and track record
Lantheus reports on Nov 5, 2026, before the open (37 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 37 days away
- EPS estimate
- $1.25
- Revenue estimate
- $360.9M
4 of 8reports beat the EPS estimate
±11%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Feb 19, 2026 AI summary
- What they said
- Lantheus completed strategic acquisitions of Neuraceq (Alzheimer's PET diagnostic) and OCTEVY (neuroendocrine PET diagnostic under FDA review) while divesting legacy SPECT business on January 1, 2026. Products served approximately 7 million patients in 2025. Company maintained leadership in PSMA PET imaging with PYLARIFY and advanced Lantheus 2401 for prostate cancer patients who are PSMA negative.
- Guidance
- New PSMA PET formulation launch planned for Q4 2026 with material commercial impact beginning in 2027. Neuraceq growth expected to exceed overall amyloid PET imaging market in 2026.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Feb 19, 2026 | $1.67 est $1.16 | $406.8M est $367.0M | +1.1% |
| Nov 6, 2025 | $1.27 est $1.27 | $384.0M est $368.0M | −10.8% |
| Aug 6, 2025 | $1.57 est $1.64 | $378.0M est $363.3M | −24.5% |
| Apr 30, 2025 | $1.53 est $1.65 | $372.8M est $395.2M | +1.9% |
| Feb 20, 2025 | $1.59 est $1.54 | — | −3.9% |
| Nov 6, 2024 | $1.70 est $1.56 | $378.7M est $375.9M | −23.2% |
| Jul 31, 2024 | $1.80 est $1.83 | $394.1M est $382.2M | −10.2% |
| May 2, 2024 | $1.69 est $1.54 | $370.0M est $382.2M | +12.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Lantheus stock forecast and analyst price targets
Analysts’ average 12-month price target for Lantheus is $107.74, +8.0% from the last close, from 9 firms rating the stock in the last 90 days.
$107.74consensus 12-month target, +8.0% from the last close
Now $99.74Avg $107.74
Low $102.50High $115
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 17 | B. Riley Securities | $105.40 | +5.7% |
| Aug 14 | JonesTrading | — | — |
| Aug 8 | William Blair | — | — |
| Aug 6 | William Blair | — | — |
| Aug 4 | CJS Securities | — | — |
+4.4%average 20-day move after past Accumulation readings
+1.7%average move over the next 20 trading days in the last 5 years
±0.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Lantheus seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Lantheus averaged +1.7% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.2% | 4 of 5 |
| Next 10 trading days | +0.6% | 3 of 5 |
| Next 15 trading days | +3.0% | 4 of 5 |
| Next 20 trading days | +1.7% | 3 of 5 |
| Next 30 trading days | −4.7% | 2 of 5 |
For scale, LNTH’s typical 20-trading-day move in either direction is about 9.2%.
Lantheus market cap and key statistics
Lantheus’s market cap is $6.49B, with a P/E ratio of 23.9 and revenue of $1.56B over the last twelve months.
Valuation
- Market cap
- $6.49B
- P/E ratio
- 23.9
- Forward P/E
- 14.3
- EPS, TTM
- $4.18
- Gekko Fair Value
- $172.53
Trading
- Volume
- 1.20M
- Avg volume, 20 days
- 942,532
- 52-week high
- $111.86
- 52-week low
- $49.67
- Shares outstanding
- 65.30M
Financials
- Revenue, TTM
- $1.56B
- Profit margin
- 17.7%
- Return on equity
- 22.2%
- Quarterly earnings growth, YoY
- −0.9%
Risk and income
- Beta
- -0.03
- Typical daily move
- ±0.4%
- Typical 20-day move
- ±9.2%
Lantheus stock news this week
Coverage of Lantheus this week reads positive: 7 positive, 2 neutral and 0 negative headlines.
- Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate CancerGlobeNewsWire, Sep 28
- Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA ApprovalYahoo Finance, Sep 26
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)mykxlg.com, Sep 24
- Lantheus Holdings (LNTH) Wins FDA Approval For BRAVNETSA, Is 7% Undervalued Enough?Simply Wall Street, Sep 24
- Lantheus wins FDA approval for Bravnetsa GEP-NET drugMugglehead Investment Magazine, Sep 23
- Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) RallyYahoo Finance, Sep 23
Lantheus peers
Lantheus’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
Lantheus stock FAQ
What is Lantheus’s market cap?
Lantheus’s market cap is $6.49B at the Sep 28, 2026 close of $99.74, with 65.30M shares outstanding. The shares trade on a P/E ratio of 23.9.
What is the Lantheus stock forecast?
The consensus analyst 12-month price target for Lantheus is $107.74, +8.0% from the last close. Of the 9 firms that rated the stock in the last 90 days, 1 rate it a buy, 8 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Lantheus stock overvalued or undervalued?
On Gekko’s estimate Lantheus is undervalued: the Sep 28, 2026 close of $99.74 is 42.2% below Gekko Fair Value of $172.53. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Lantheus report earnings next?
Lantheus is expected to report on Nov 5, 2026, before the market opens (37 days away). Analysts expect earnings of $1.25 per share on revenue of $360.9M. Lantheus beat the earnings estimate in 4 of its last 8 reports, moving 11% on average across the report.
What is Lantheus’s 52-week high and low?
Lantheus’s 52-week high is $111.86 and its 52-week low is $49.67; it closed at $99.74 on Sep 28, 2026, +93.8% over the past year. Over the last five years the shares peaked at $126.89 on Jul 16, 2024.
Is Lantheus stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Lantheus the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.